{"schema_version":"1.0","type":"article","title":"20年後，HDAC抑制劑終於找到真正的位置？ABT-301能否成為下一代聯合治療骨幹","url":"https://drugnews.com.tw/articles/2026-08-11-anbogen-abt301-next-generation-hdaci-backbone.html","markdown_url":"https://drugnews.com.tw/articles/2026-08-11-anbogen-abt301-next-generation-hdaci-backbone.md","lang":"zh-Hant","date":"2026-08-11","publish_at":"2026-08-11T08:00:00+08:00","updated_at":"2026-08-11","category":"商業分析系列","topic":"商業分析系列","tags":["安邦生技","ABT-301","imofinostat","HDAC抑制劑","Chidamide","pMMR大腸直腸癌","癌症免疫治療","台灣生技"],"summary":"Chidamide以pMMR大腸癌44% ORR與黑色素瘤第三期PFS達標，重新降低HDAC抑制劑的類別風險；安邦ABT-301接下來必須用治療窗口、三聯可組合性與人體免疫機轉，證明資產差異。","key_points":[],"facts":[],"sections":["一、HDAC抑制劑真正卡住的，不是藥效，而是可持續性","二、Chidamide完成類別去風險，但也留下升級空間","三、ABT-301的差異化：不是「強16倍」，而是臨床窗口","四、23位一期病人：人體證據足以推進，但不足以定調","五、三聯試驗是決勝點：不只看反應率，還要過四道關","六、ABT-301市場滲透路徑：適應症底價、跨癌種擴張與平台溢價","結語：Chidamide證明類別，ABT-301必須證明資產","參考資料"],"references":[{"title":"[HUYABIO International Delivers Significant Landmark Phase 3 Results in Advanced Melanoma]","source":"","date":"","url":"https://huyabio.com/huyabio-international-delivers-significant-landmark-phase-3-results-in-advanced-melanoma/"},{"title":"[Combined anti-PD-1, histone deacetylase inhibitor and anti-VEGF treatment in MSS/pMMR colorectal cancer (Nature Medicine, CAPability-01)]","source":"","date":"","url":"https://www.nature.com/articles/s41591-024-02813-1"},{"title":"[Phase I first-in-human trial of ABT-301, an oral pan-HDAC inhibitor in patients with advanced solid tumors (JCO 2023 abstract e15137)]","source":"","date":"","url":"https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.e15137"},{"title":"[Imofinostat - NCI Drug Dictionary]","source":"","date":"","url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/imofinostat"},{"title":"[Anbogen Therapeutics - ABT-301 clinical and AACR updates]","source":"","date":"","url":"https://anbogen.com/en/news/cCCcD7dA6dcf"},{"title":"[ClinicalTrials.gov: ABT-301 + Tislelizumab + Bevacizumab in pMMR/non-MSI-H colorectal cancer]","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT07244705"},{"title":"[Chipscreen Biosciences - Chidamide/Tucidinostat development history]","source":"","date":"","url":"https://www.chipscreen.com/en/news/company-news/1178.html"},{"title":"[Phase II randomized trial of first-line pembrolizumab and vorinostat in metastatic NSCLC: final results]","source":"","date":"","url":"https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.9125"},{"title":"[Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial]","source":"","date":"","url":"https://www.nature.com/articles/s43018-025-01004-2"},{"title":"[安邦興櫃前法說會簡報 (2026)]","source":"","date":"","url":"https://mopsov.twse.com.tw/nas/STR/778420260429E001.pdf"},{"title":"[Credence Research: Global Checkpoint Inhibitor Refractory Cancer Drugs Market]","source":"","date":"","url":"https://www.credenceresearch.com/report/checkpoint-inhibitor-refractory-cancer-market"},{"title":"[Pancreatic Cancer Market Size and Forecase 2026-2035 (Research Nester)]","source":"","date":"","url":"https://www.researchnester.com/reports/pancreatic-cancer-market/5299"},{"title":"[Brain Cancer Market Trends for 2026 (Towards Healthcare)]","source":"","date":"","url":"https://www.towardshealthcare.com/insights/brain-cancer-market-sizing"},{"title":"[Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer]","source":"","date":"","url":"https://ir.revmed.com/news-releases/news-release-details/daraxonrasib-demonstrates-unprecedented-overall-survival-benefit/"}],"images":[{"alt":"圖1｜HDAC抑制劑二十年真正卡住的三道牆：安全性與可組合性、治療窗口太窄，以及早期反應無法穩定轉化為無惡化存活與整體存活。","url":"https://drugnews.com.tw/assets/articles/anbogen-abt301-next-generation-hdaci-backbone/figure-01.png"},{"alt":"圖2｜Chidamide（西達本胺）完成兩項實體瘤驗證：CAPability-01在MSS轉移性大腸直腸癌取得44%客觀緩解率；HBI-8000加nivolumab則在黑色素瘤全球第三期達成主要無惡化存活終點，但骨髓毒性與聯用負擔仍需持續比較。","url":"https://drugnews.com.tw/assets/articles/anbogen-abt301-next-generation-hdaci-backbone/figure-02.png"},{"alt":"圖3｜ABT-301的差異化證據鏈：由HDAC3標靶、免疫微環境與抗藥路徑，逐步連到人體暴露與聯合治療驗證。","url":"https://drugnews.com.tw/assets/articles/anbogen-abt301-next-generation-hdaci-backbone/figure-03.png"},{"alt":"圖4｜ABT-301第一期人體訊號：已建立安全性、初步活性與治療窗口的推進依據，但尚未形成比較性證據。","url":"https://drugnews.com.tw/assets/articles/anbogen-abt301-next-generation-hdaci-backbone/figure-04.png"},{"alt":"圖5｜pMMR大腸直腸癌三聯試驗的四階段評估：先證明可組合性，再看療效、持久性與人體機制，決定ABT-301能否升級為聯合治療骨幹。","url":"https://drugnews.com.tw/assets/articles/anbogen-abt301-next-generation-hdaci-backbone/figure-05.png"},{"alt":"圖6｜ABT-301的價值解鎖路徑：MSS大腸癌建立資產底價，胰臟癌與腦腫瘤提供跨癌種選擇權，多種搭配藥物重現後才形成平台溢價；圖中市場數字僅作需求估算。","url":"https://drugnews.com.tw/assets/articles/anbogen-abt301-next-generation-hdaci-backbone/figure-06.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/anbogen-abt301-next-generation-hdaci-backbone/cover-1400.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-08-11）。20年後，HDAC抑制劑終於找到真正的位置？ABT-301能否成為下一代聯合治療骨幹。https://drugnews.com.tw/articles/2026-08-11-anbogen-abt301-next-generation-hdaci-backbone.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-08-11-anbogen-abt301-next-generation-hdaci-backbone-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}